Finally, NRG1 fusion partners were most commonly ATP1B1 (pancreatic cancer) or CD74 (NSCLC) in FDA-approved indications, with a mix of these as well as SLC3A2 and RBPMS being commonly observed partner genes in nonapproved indications. This evidence concerns the gene RBPMS and familial pancreatic carcinoma.